RxDoctor Payments Data

Innocent Odocha, MD

Family Medicine · Gainesville, FLNPI 1568560829

Payments from drug & device makers

$2,833in general payments, 2019–2025

Across 157 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$433
  • Lilly USA, LLC$414
  • Sanofi-aventis U.S. LLC$280
  • Abbott$214
  • Pfizer$202
  • Novo Nordisk$193
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$2,833100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,833 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$276,725
Medicare patients
233
Services billed
3,423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide89$110,032
EliquisApixaban85$91,532
Breztri AerosphereBudesonide/Glycopyr/Formoterol38$53,939
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$42,668
JardianceEmpagliflozin27$38,155
EntrestoSacubitril/Valsartan12$15,946
FarxigaDapagliflozin Propanediol14$14,633
MyrbetriqMirabegron14$13,871
LinzessLinaclotide14$13,585
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen301$6,526
Lantus SolostarInsulin Glargine,hum.Rec.Anlog66$6,279
Tresiba Flextouch U-100Insulin Degludec14$5,786
Atorvastatin Calcium286$2,162
Testosterone Cypionate46$2,122
Albuterol Sulfate HfaAlbuterol Sulfate48$2,085

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$193$110,03289 claims
PfizerEliquis$202$91,53285 claims
AstraZenecaBreztri Aerosphere, Farxiga$433$68,57252 claims
GSKTrelegy Ellipta$152$42,66832 claims
Boehringer IngelheimJardiance$62$38,15527 claims
NovartisEntresto$96$15,94612 claims
Astellas Pharma US IncMyrbetriq$48$13,87114 claims
AbbVieLinzess$14$13,58514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →